Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hutchmed
EpicentRx, Inc.
Hoffmann-La Roche
University of California, San Francisco
Eli Lilly and Company
Stanford University
Merck Sharp & Dohme LLC